Elicera Therapeutics AB. (10/5/20). "Press Release: Elicera Therapeutics Completes Oversubscribed Share Issue and Secures 13,2 MSEK in Financing".

	Product	cancer immunotherapy (immuno-oncology, I-O)
	Product 2	venture capital
	Person	El-Mosleh, Jamal (Immunicum AB 200709– CEO)

Elicera Therapeutics announced today that it has completed its first share issue and secured 13,2 MSEK in financing to launch unique immuno-oncology company based on groundbreaking research by professor Magnus Essand's research group at Uppsala University. Jamal El-Mosleh is announced as Elicera's CEO.

Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses

Read the press release in Swedish:
Download press release (pdf)
[ https://assets.website-files.com/5e85ca7e8347401d65425175/5f79c0da34c371e7c3b909b2_Pressmeddelande%20Elicera%20Therapeutics%20201005%20-%20Genomförd%20finansiering.pdf ]

Record changed: 2020-12-09